Effects of Tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-16010028

Enrollment

Unknown

Registered

2016-11-23

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

double-dose TW (DTW) group:?????120mg

Prednisone (PRE) group:1mg/kg prednisone once daily

conventional-dose TW (CTW) group:60 mg TW daily

Eligibility

Sex/Gender

All

Age

21 Years to 54 Years

Inclusion criteria

Inclusion criteria: IgAN and heavy proteinuria (=3.5 g/24 h)

Exclusion criteria

Exclusion criteria: Patients with other causes of IgA-positive glomerular staining, such as Henoch-Schnlein nephritis and lupus nephritis, were excluded. The coincidence of IgAN and minimal change disease confirmed by electron microscopy was also excluded from the study.

Design outcomes

Primary

Measure	Time frame
proteinuria;	—

Contacts

Public ContactLi-na Zhou

Shanghai Tenth People's Hospital, Tongji University School of Medicine

wang.zhen@tongji.edu.cn+86 15901989527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026